Перейти
на сайт журнала "Врач" |
Перейти на сайт журнала "Медицинская сестра"
|
Перейти на сайт журнала "Фармация"
|
Перейти на сайт журнала "Молекулярная медицина"
|
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
|
Журнал включен в российские и международные библиотечные и реферативные базы данных
ВАК (Россия)
|
РИНЦ (Россия)
|
Эко-Вектор (Россия)
|
ФИБРОЗ ЛЕГКИХ У ПЕРЕНЕСШИХ COVID-19: ИНГИБИТОРЫ ГИСТОНОВЫХ ДЕАЦЕТИЛАЗ КАК ПЕРСПЕКТИВНАЯ ТЕРАПЕВТИЧЕСКАЯ СТРАТЕГИЯ
DOI: https://doi.org/10.29296/25877313-2021-08-01
Номер журнала:
8
Год издания:
2021
За последние двадцать лет мир стал свидетелем нескольких вирусных эпидемий, таких как эпидемии коронавируса тяжелого острого респира-торного синдрома (SARS-CoV), вируса гриппа A подтипа H1N1, коронавируса ближневосточного респираторного синдрома (MERS-CoV), а недавно и нового коронавируса SARS-CoV-2, вызвавшего заболевание COVID-19. Последняя эпидемия оказалась наиболее разрушительной и унесла с со-бой более 2 млн человеческих жизней. Сегодняшние усилия в борьбе с COVID-19 направлены, в основном, на контроль распространения коро-навируса и определение эффективных вариантов лечения. Между тем анализ данных, касающихся долговременных клинических последствий предыдущих коронавирусных инфекций (SARS-CoV и MERS-CoV), показывает, что с выведением вируса из организма патологический процесс во многих случаях не завершается и может перерасти в длительное поражение легких, в частности, фиброзное интерстициальное заболевание, или фиброз легких. Таким образом, фиброз легких может стать постоянной проблемой у пациентов, выздоровевших от COVID-19. Поэтому необ-ходимо уже сейчас определить стратегию превентивных мер как по противодействию развития фиброза легких у пациентов с COVID-19 в период стационарного лечения, так и по недопущению его возникновения и прогрессирования в отдаленной перспективе. Такие антифибротические препараты, как пирфенидон и нинтеданиб показали свою эффективность в снижении скорости ухудшения функции легких, тем не менее ре-зультаты их применения не дали существенного улучшения в выздоровлении пациентов. Кроме того, прием этих препаратов был связан с разви-тием серьезных побочных эффектов. В этой связи, цель работы – рассмотреть возможность использования ингибиторов гистондеацетилазы (HDAC, histonedeacetylase) в качестве альтернативной эпигенетической стратегии терапии для предотвращения развития или прогрессирования легочного фиброза у выздоровевших пациентов с SARS-CoV-2
Ключевые слова:
COVID-19
SARS-CoV-2
легочный фиброз
TGF-β
ингибиторы HDAC
эпигенетика
Для цитирования:
Айтбаев К.А., Муркамилов И.Т., Муркамилова Ж.А., Фомин В.В., Кудайбергенова И.О., Юсупов Ф.А. ФИБРОЗ ЛЕГКИХ У ПЕРЕНЕСШИХ COVID-19: ИНГИБИТОРЫ ГИСТОНОВЫХ ДЕАЦЕТИЛАЗ КАК ПЕРСПЕКТИВНАЯ ТЕРАПЕВТИЧЕСКАЯ СТРАТЕГИЯ
. Вопросы биологической, медицинской и фармацевтической химии, 2021; (8): -https://doi.org/10.29296/25877313-2021-08-01
Список литературы:
- Wang H., Li X., Li T., et al. The genetic sequence, origin, and diag-nosis of SARS- CoV-2. Eur. J. Clin. Microbiol. Infect. Dis. Off Publ. Eur. Soc. Clin. Microbiol. 2020; https://doi.org/10.1007/s10096-020-03899-4
- CDC, Coronavirus disease 2019 (COVID-19), in: Cent. Dis. Con-trol Prev, 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/evidence-table.html. (Accessed 25 July 2020).
- Gu J., Korteweg C. Pathology and pathogenesis of severe acute respiratory syndrome. Am. J. Pathol 2007; 170:1136–1147. https://doi.org/10.2353/ ajpath.2007.061088
- Zhang P., Li J., Liu H., et al. Long-term bone and lung conse-quences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. 2020; 8: 8. https://doi.org/10.1038/ s41413-020-0084-5
- Tse G.M., To K.F., Chan P.K., et al. Pulmonary pathological fea-tures in coronavirus associated severe acute respiratory syndrome (SARS). J. Clin. Pathol. 2004; 57: 260–265. https://doi.org/10.1136/jcp.2003.013276
- Antonio G.E., Wong K.T., Hui D.S., et al. Thin-section CT in pa-tients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003; 228: 810–815. https://doi.org/10.1148/radiol.2283030726
- Wong K.T., Antonio G.E., Hui D.S., et al. Severe acute respiratory syndrome: thin- section computed tomography features, temporal changes, and clinicoradiologic correlation during the convalescent period. J. Comput. Assist. Tomogr. 2004; 28: 790–795. https://doi.org/10.1097/00004728-200411000-00010
- Wu X., Dong D., Ma D. Thin-section computed tomography manifestations during convalescence and long-term follow-up of patients with severe acute respiratory syndrome (SARS). Med. Sci. Monit. Int. Med. J. Exp.Clin. Res. 2016; 22: 2793–2799. https://doi.org/10.12659/msm.896985
- Müller N.L., Ooi G.C., Khong P.L., et al. High-resolution CT find-ings of severe acute respiratory syndrome at presentation and after admission. AJR Am. J. Roentgenol. 2004; 182:
- 39–44. https://doi.org/10.2214/ajr.182.1.1820039
- Chu W.C., Li A.M., Ng A.W., et al. Thin-section CT 12 months after the diagnosis of severe acute respiratory syndrome in pediatric pa-tients. AJR Am. J. Roentgenol. 2006; 186: 1707–1714. https://doi.org/10.2214/AJR.05.0382
- Das K.M., Lee E.Y., Singh R., et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J. Ra-diol. Imaging. 2017; 27: 342–349. https://doi.org/10.4103/ijri.IJRI_469_16
- Mossel E.C., Wang J., Jeffers S., et al. SARS-CoV replicates in primary human alveolar type II cell cultures but not in type I-like cells. Virology. 2008; 372: 127–135. https://doi.org/10.1016/j.virol.2007.09.045
- Weinheimer V.K., Becher A., Tönnies M., et al. Influenza A viruses target type II pneumocytes in the human lung. J. Infect. Dis. 2012; 206: 1685–1694. https://doi. org/10.1093/infdis/jis455
- Delpino M.V., Quarleri J. SARS-CoV-2 pathogenesis: imbalance in the renin- angiotensin system favors lung fibrosis. Front. Cell. Infect. Microbiol. 2020; 10: 340. https://doi.org/10.3389/fcimb.2020.00340
- Коган Е.А., Березовский Ю.С., Проценко Д.Д. и др. Патологи-ческая анатомия инфекции, вызванной SARS-CoV-2. Судебная медицина. 2020; 6(2): 8–30. https://doi.org/ 10.19048/2411-8729-2020-6-2-8-30 (Kogan E.A., Berezovsky Yu.S, Protsenko D.D., et al. Pathological Anatomy of Infection Caused by SARS-CoV-2. Russian Journal of Forensic Medicine. 2020; 6(2): 8–30. https://doi.org/ 10.19048/2411-8729-2020-6-2-8-30 (in Russian)].
- Ni W., Yang X., Yang D., et al. Role of angiotensin-converting en-zyme 2 (ACE2) in COVID-19. Crit Care Lond Engl. 2020; 24: 422. https://doi.org/10.1186/s13054- 020-03120-0
- Leng L., Cao R., Ma J., et al. Pathological features of COVID-19-associated lung injury: a preliminary proteomics report based on clinical samples. Signal Transduct Target Ther. 2020; 5: 240. https://doi.org/10.1038/s41392-020-00355-9
- Meyer K.C. Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosis. Expert Rev Respir Med. 2017; 11: 343–359. https://doi.org/10.1080/ 17476348.2017.1312346
- Richeldi L., Collard H.R., Jones M.J. Idiopathic pulmonary fibro-sis. Lancet Lond Engl. 2017 389: 1941–1952. https://doi.org/10.1016/S0140-6736(17)30866-8
- Vallʹee A., Lecarpentier Y. TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts. Cell Biosci. 2019; 9: 98. https://doi.org/10.1186/ s13578-019-0362-3
- Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol. 2008;214:199–210. https://doi.org/10.1002/path.2277
- Pardo A., Cabrera S., Maldonado M., Selman M. Role of matrix metalloproteinases in the pathogenesis of idiopathic pulmonary fibrosis. Respir. Res. 2016; 17: 23. https://doi.org/10.1186/s12931-016-0343-6
- George P.M., Wells A.U., Jenkins R.G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir. Med. 2020; https://doi.org/ 10.1016/S2213-2600(20)30225-3
- Leask A. COVID-19: is fibrosis the killer? J. Cell. Commun. Sig-nal. 2020; 14: 255. https://doi.org/10.1007/s12079-020-00569-0
- Wu C., Chen X., Cai Y., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with corona-virus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020; https://doi.org/10.1001/ jamainternmed.2020.0994
- Yu M., Liu Y., Xu D., et al. Prediction of the development of pulmo-nary fibrosis using serial thin-section CT and clinical features in pa-tients discharged after treatment for COVID-19 pneumonia. Korean J. Radiol. 2020; 21: 746–755. https://doi.org/10.3348/kjr.2020.0215
- MGH FLARE. June 2 - will COVID-19 cause more IPF? https://us19.campaign-archive.com/?u=ef98149bee3f299584374540a&id=737fad9de0. (Accessed 28 November 2020).
- Ojo A.S., Balogun S.A., Williams O.T., Ojo O.S. Pulmonary fibro-sis in COVID-19 survivors: predictive factors and risk reduction strategies. Pulm Med. 2020;2020:6175964. https://doi.org/10.1155/2020/6175964
- Wigén J., Löfdahl A., Bjermer L., et al. Converging pathways in pulmonary fibrosis and Covid-19 - the fibrotic link to disease se-verity. Respir Med X. 2 2020; 100023. https://doi.org/10.1016/j.yrmex.2020.100023
- Kobayashi T., Tanaka K., Fujita T., et al. Bidirectional role of IL-6 signal in pathogenesis of lung fibrosis. Respir. Res. 2015; 16: 99. https://doi.org/10.1186/ s12931-015-0261-z
- Пустоветова М.Г., Чикинев Ю.А., Пионтковская К.А. Моле-кулярно-клеточные механизмы развития фиброза легких и спонтанного пневмоторакса. Бюллетень СО РАМН. 2014; 34(5): 17-21 [Pustovetova M.G., Chikinev Yu.A., Piontkovskaya K.A. Molecular cell mechanisms of development of pulmonary fi-brosis and spontaneous pneumothorax. Bulletin of the SB RAMS 2014; 34(5): 17-21 (in Russian)].
- Minshall E.M., Leung D.Y., Martin R.J., et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am. J. Respir. Cell Mol. Biol. 1997; 17: 326–333. https://doi.org/10.1165/ajrcmb.17.3.2733
- Khalil N., O’Connor R.N., Flanders K.C., et al. TGF-beta 1, but not TGF-beta 2 or TGF-beta 3, is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. Am. J. Respir. Cell Mol. Biol. 1996; 14:131–138. https://doi.org/10.1165/ajrcmb.14.2.8630262
- Khalil N., Parekh T.V., O’Connor R., et al. Regulation of the ef-fects of TGF-beta 1 by activation of latent TGF-beta 1 and differen-tial expression of TGF-beta receptors (T beta R-I and T beta R-II) in idiopathic pulmonary fibrosis. Thorax. 2001; 56:907–915. https://doi.org/10.1136/thorax.56.12.907
- Roberts A.B., Piek E., Böttinger E.P., et al. Is Smad3 a major player in signal transduction pathways leading to fibrogenesis? Chest. 2001; 120: 43S–47S. https:// doi.10.1378/chest.120.1_suppl.s43-a
- Leask A., Abraham D.J. TGF-beta signaling and the fibrotic re-sponse. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2004; 18:816–827. https://doi.org/10.1096/fj.03-1273rev
- Kandasamy M., Lehner B., Kraus S., et al. TGF-beta signalling in the adult neurogenic niche promotes stem cell quiescence as well as generation of new neurons. J. Cell. Mol. Med. 2014; 18: 1444–1459. https://doi.org/10.1111/ jcmm.12298
- Venkataraman T., Frieman M.B. The role of epidermal growth fac-tor receptor (EGFR) signaling in SARS coronavirus-induced pul-monary fibrosis. Antivir. Res. 2017; 143: 142–150. https://doi.org/10.1016/j.antiviral.2017.03.022
- Watanabe-Takano H., Takano K., Hatano M., et al. DA-Raf-mediated suppression of the Ras-ERK pathway is essential for TGF-β1-induced epithelial-mesenchymal transition in alveolar epi-thelial type 2 cells. PLoS One. 2015; 10:e0127888. https://doi.org/10.1371/journal.pone.0127888
- Zhao X., Nicholls J.M., Chen Y.G. Severe acute respiratory syn-drome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. J. Biol. Chem. 2008; 283: 3272–3280. https://doi.org/10.1074/jbc.M708033200
- Allen J.T., Knight R.A., Bloor C.A., et al. Enhanced insulin-like growth factor binding protein-related protein 2 (connective tissue growth factor) expression in patients with idiopathic pulmonary fi-brosis and pulmonary sarcoidosis. Am. J. Respir. Cell Mol. Biol. 1999; 21: 693–700. https://doi.org/ 10.1165/ajrcmb.21.6.3719
- Torr E.E., Ngam C.R., Bernau K., et al. Myofibroblasts exhibit en-hanced fibronectin assembly that is intrinsic to their contractile phe-notype. J. Biol. Chem. 2015; 290: 6951–6961. https://doi.org/10.1074/jbc.M114.606186
- Desmouliʹere A., Geinoz A., Gabbiani F., et al. Transforming growth factor- beta 1 induces alpha-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 1993; 122: 103–111. https://doi.org/10.1083/jcb.122.1.103
- Rajasekaran S., Vaz M., Reddy S.P. Fra-1/AP-1 transcription factor negatively regulates pulmonary fibrosis in vivo. PLoS One. 2012; 7:e41611. https://doi.org/ 10.1371/journal.pone. 0041611
- Shi K., Jiang J., Ma T., et al. Pathogenesis pathways of idiopathic pulmonary fibrosis in bleomycin-induced lung injury model in mice. Respir. Physiol. Neurobiol. 2014; 190: 113–117. https://doi.org/10.1016/j.resp.2013.09.011
- Pattarayan D., Rajarajan D., Ayyanar S., et al. C-phycocyanin suppresses transforming growth factor-β1-induced epithelial mes-enchymal transition in human epithelial cells. Pharmacol Rep PR. 2017; 69: 426–431. https://doi.org/ 10.1016/j.pharep.2016.12.013
- Pattarayan D., Thimmulappa R.K., Ravikumar V., Rajasekaran S. Diagnostic potential of extracellular microRNA in respiratory diseases. Clin. Rev. Allergy Immunol. 2018; 54: 480–492. https://doi.org/10.1007/s12016-016-8589-9
- Rajasekaran S., Rajaguru P., Sudhakar Gandhi P.S. MicroRNAs as potential targets for progressive pulmonary fibrosis. Front. Pharmacol. 2015; 6: 254. https://doi. org/10.3389/fphar.2015.00254
- Myllärniemi M., Kaarteenaho R. Pharmacological treatment of idiopathic pulmonary fibrosis - preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine. EurClinRespir J. 2015; 2. https://doi.org/10.3402/ecrj. v2.26385
- Margaritopoulos G.A., Vasarmidi E., Antoniou K.M. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid 2016; 11: 11–22. https://doi.org/10.2147/CE.S76549
- Kato M., Sasaki S., Nakamura T., et al. Gastrointestinal adverse ef-fects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci. Rep. 2019; 9: 12062. https://doi.org/10.1038/s41598-019-48593-4
- Zhang H. A Randomized Open-label Study to Evaluate the Efficacy and Safety of Pirfenidone in Patients With Severe and Critical Novel Coronavirus Infection. Сlinic. altrials. Gov. 2020.
- Pleasants R., Tighe R.M. Management of idiopathic pulmonary fi-brosis. Ann. Pharmacother. 2019; 53: 1238–1248. https://doi.org/10.1177/ 1060028019862497
- Tang J., Yan H., Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin. Sci (Lond.). 2013 jun; 124(11): 651–662. https://doi.org/1042/CS20120504
- Glenisson W., Castronovo V., Waltregny D. Histone deacetylase 4 is required for TGFbeta1-induced myofibroblastic differentiation. Biochim. Biophys. Acta. 2007; 1773: 1572–1582. https://doi.org/10.1016/j.bbamcr.2007.05.016
- Guo W., Shan B., Klingsberg R.C., et al. Abrogation of TGF-beta1-induced fibroblast-myofibroblast differentiation by histone deacety-lase inhibition. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2009; 297: L864–L870. https://doi.org/10.1152/ ajplung.00128.2009
- Korfei M., Skwarna S., Henneke I., et al. Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fi-brosis. Thorax. 2015; 70: 1022–1032. https://doi.org/10.1136/thoraxjnl-2014-206411
- Barter M.J., Pybus L., Litherland G.J., et al. HDAC-mediated con-trol of ERK- and PI3K-dependent TGF-β-induced extracellular ma-trix-regulating genes. Matrix. Biol. J. Int. Soc. Matrixю Biol. 2010; 29: 602–612. https://doi.org/10.1016/j. matbio.2010.05.002
- Jones D.L., Haak A.J., Caporarello N., et al. TGFβ-induced fibro-blast activation requires persistent and targeted HDAC-mediated gene repression. J. Cell Sci. 2019; 132. https://doi.org/10.1242/jcs.233486
- Saito S., Zhuang Y., Suzuki T., et al. HDAC8 inhibition ameliorates pulmonary fibrosis. Am. J. Physiol. Lung. Cell. Mol. Physiol. 2019; 316: L175–L186. https://doi. org/10.1152/ajplung.00551.2017
- Yoon S., Kang G., Eom G.H. HDAC inhibitors: therapeutic poten-tial in fibrosis-associated human diseases. Int. J. Mol. Sci. 2019; 20. https://doi.org/10.3390/ ijms20061329
- Coward W.R., Watts K., Feghali-Bostwick C.A., et al. Defective histone acetylation is responsible for the diminished expression of cyclooxygenase 2 in idiopathic pulmonary fibrosis. Mol. Cell. Biol. 2009; 29: 4325–4339. https://doi.org/ 10.1128/MCB.01776-08
- Huang S.K., Scruggs A.M., Donaghy J., et al. Histone modifica-tions are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell. Death Dis. 2013;4:e621. https://doi.org/10.1038/cddis.2013.146
- Saito S., Zhuang Y., Shan B., et al. Tubastatin ameliorates pulmo-nary fibrosis by targeting the TGFβ-PI3K-Akt pathway. PLoS One. 2017; 12:e0186615. https://doi. org/10.1371/ journal.pone.0186615
- Korfei M., Stelmaszek D., MacKenzie B., et al. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor pano-binostat versus the IPF-drug pirfenidone in fibroblasts from pa-tients with idiopathic pulmonary fibrosis. PLoS One. 2018; 13:e0207915. https://doi.org/10.1371/journal. pone.0207915